STAT3 and hepatocellular carcinoma: Regorafenib-mediated STAT3 inhibition was due to an increase in SHP-1 tyrosine phosphatase activity by direct impairment of the association between N-SH2 and the catalytic domain of SHP-1, as we have already described in the HCC section.